Skip to main
CLGN
CLGN logo

CLGN Stock Forecast & Price Target

CLGN Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

CollPlant Biotechnologies Ltd is strategically enhancing its rhCollagen supply through an expanded agreement with STEMCELL Technologies, which positions the company favorably for growth in the North American market. The company's progress with regenerative breast implants and the innovative Collink.3D technology demonstrates superior properties compared to existing solutions, potentially allowing CollPlant to capture significant market share against established competitors. Additionally, the new distribution agreement in Poland for the Vergenix STR product expands its European market presence, further supporting the company’s positive growth trajectory.

Bears say

CollPlant Biotechnologies Ltd faces a challenging financial landscape characterized by limited revenue streams derived primarily from collaborations and product sales, which may hinder its ability to achieve sustainable growth. The dependence on emerging markets, notably for its rhCollagen in medical aesthetics and BioInk for 3D bioprinting, raises concerns about market volatility and potential regulatory hurdles. Additionally, the company's operations in various regions, including the United States and Europe, may be impacted by competitive pressures and evolving healthcare demands, contributing to an overall negative outlook on its stock performance.

CLGN has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CollPlant Biotechnologies Ltd - ADR and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CollPlant Biotechnologies Ltd - ADR (CLGN) Forecast

Analysts have given CLGN a Strong Buy based on their latest research and market trends.

According to 2 analysts, CLGN has a Strong Buy consensus rating as of Nov 26, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CollPlant Biotechnologies Ltd - ADR (CLGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.